Demystifying basal‐like breast carcinomas
AUTOR(ES)
Da Silva, L
FONTE
BMJ Group
RESUMO
“Basal” breast cancers are dominating the breast research literature at present and pathologists are under increasing pressure to evaluate for such a phenotype by their surgical and oncological colleagues. There is also much confusion about how to assess cancers, which immunohistochemical markers to use, what meaning and benefit this provides, and what the surgeons and oncologists will do with the information. Much remains to be done to answer all these questions but here we try to shed light on some of the issues and suggest what is still to come.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2095578Documentos Relacionados
- Vimentin and laminin expression is associated with basal‐like phenotype in both sporadic and BRCA1‐associated breast carcinomas
- Albumin‐bound paclitaxel (ABI‐007; Abraxane) in the management of basal‐like breast carcinoma
- Avaliação do significado clínico do subtipo basal-like de câncer de mama identificado através de imunohistoquímica
- Breast carcinomas in patients on HRT.
- The treatment of periocular basal cell carcinomas by radiotherapy.